Investors
Infrastructure for mental-health care that has to be built responsibly
BioTekk is a development-stage UK company building a continuous mental wellbeing support and intelligence platform. This page sets out the context we are working in, the stage we are genuinely at, and how qualified investors can request current materials.
01 — Context
Demand is continuous. Contact is episodic.
Mental-health need does not arrive in appointment-sized units. It accumulates between contacts, and by the time it becomes visible to a service, the opportunity for a small, timely intervention has often passed. That gap is not a marketing observation — it is the structural problem the platform is designed to address.
Between-appointment blindness
Services make decisions from snapshots taken weeks apart. Change that happens in between is reconstructed from memory rather than observed.
Capacity is the binding constraint
Adding clinicians is slow and expensive. Helping existing clinicians see the right person sooner is a different kind of problem — and a tractable one.
Trust is the gating factor
In this category, adoption is decided by clinical safety, information governance and evaluation evidence — not by product velocity. Building for that is a moat, not a tax.
02 — Thesis
What we believe, stated plainly
Continuity is the product, not conversation
Conversational AI is now a commodity capability. The defensible asset is a longitudinal, consented, structured record of how a person's wellbeing changes — and the safety machinery that makes it usable in a care setting.
Two-sided value in one system
The same platform serves an individual who wants to be understood and an organisation that needs to allocate scarce clinical attention. Neither side alone justifies deployment; together they do.
Governance-first is a commercial strategy
Intended-purpose discipline, hazard logs, human-in-the-loop escalation and version-specific evaluation are what make an NHS, university or occupational-health deployment possible at all. We are building them now rather than retrofitting them later.
Model-agnostic architecture
Conversation, emotional-state modelling, longitudinal analysis and safety orchestration are separate services with defined boundaries, so individual components can be replaced as the underlying model landscape changes. See the architecture →
03 — Stage
Where BioTekk actually is
We would rather be believed than impressive. BioTekk is in active development. The platform is not regulatory-approved, not clinically validated, and not generally available. The following reflects our current position rather than a roadmap promise.
04 — Use of capital
What funding is for
Safety engineering
Safety orchestration, escalation logic, red-team testing and the hazard-management process that any serious deployment will be assessed against.
Evaluation & evidence
Structured evaluation across safety, response quality, subgroup performance and robustness, reported per model version and population.
Clinical & governance capability
Clinical oversight, information-governance capability and the documentation required for provider, university and employer approval processes.
Platform & integration
Interoperability work, access control, auditability and the service architecture needed to run in real organisational environments.
05 — Risk factors
The risks we would raise ourselves
Any investment in a development-stage company carries the risk of total loss of capital. The factors below are material and are not exhaustive; the current investor materials set them out in full.
Regulatory classification
Depending on final intended purpose and functionality, parts of the platform may fall within medical-device regulation, which would materially affect cost, timelines and market entry.
Clinical evidence risk
Evaluation may not demonstrate the effect sizes required for adoption, or may show performance differences between population subgroups that require redesign.
Procurement cycles
Healthcare, higher-education and enterprise buying cycles are long and governance-gated. Revenue timing is difficult to forecast and may slip materially.
Model dependency
The platform depends on third-party foundation models whose pricing, availability, terms and behaviour may change. Architecture mitigates but does not remove this exposure.
Data protection & security
The platform processes sensitive personal data. A security or governance failure would carry regulatory, reputational and commercial consequences.
Competition & consolidation
Larger platform and EPR vendors may build adjacent capability. Our answer is depth in safety, longitudinal insight and integration rather than breadth.
Nothing on this page is an offer or invitation to subscribe for or purchase securities, an inducement to engage in investment activity, or investment, legal, tax or financial advice. Any offer would be made only through formal documentation, to persons to whom it may lawfully be made, and would be subject to the terms of that documentation. The value of an investment in an early-stage private company can go down as well as up, such investments are illiquid, and you may lose the whole of the amount invested. Please take independent professional advice before making any investment decision.
06 — Request materials
Request the current investor materials
Materials are shared with qualified investors on request. Please confirm your investor category below so we send the appropriate documentation.
What you will receive
Investor materials request
Fields marked * are required. Requests are reviewed before materials are released.
Diligence
starts here
The technology, safety and platform pages are written to be read by technical and clinical reviewers, not skimmed. Start there, then ask us the hard questions.